Clinical Trial Update: Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pyrotinib with pemetrexed and carboplatin as first-line therapy for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Pemetrexed (pemetrexed)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Fudan University | Conditions: Lung Cancer, Non-small Cell | Phase 2 | Status: UNKNOWN